Uniwersytecki Szpital Kliniczny W Poznaniu
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Uniwersytecki Szpital Kliniczny W Poznaniu, clinical research in cardiology focuses on major cardiovascular diseases such as acute coronary syndrome, acute myocardial infarction, and hypertrophic cardiomyopathy. These studies are designed to test new treatments and improve care for people at risk of recurrent heart events or living with chronic heart conditions.
- Evaluating therapies to reduce the risk of repeat heart attacks and other serious cardiovascular events
- Studying long-term treatment safety and effects in hypertrophic cardiomyopathy
- Supporting better symptom management and recovery after acute cardiac events
The research reflects a strong interest in both prevention and long-term management, with the goal of improving outcomes for patients with high-risk heart disease.
Immune System Diseases
Research in immune system diseases includes studies of systemic lupus erythematosus, discoid lupus erythematosus, and subacute cutaneous lupus erythematosus. These trials are exploring new ways to assess treatment safety, tolerability, and overall effectiveness in people affected by chronic autoimmune conditions.
- Investigating new therapies for lupus-related skin and systemic disease
- Assessing safety and tolerability in autoimmune disease treatment
- Advancing options for better disease control and patient quality of life
This work supports the development of more effective approaches for patients living with complex autoimmune disorders, where treatment needs can vary widely over time.
Neoplasms
The site also contributes to oncology research within neoplasms, particularly small cell lung cancer, large cell neuroendocrine carcinoma, and extra-pulmonary neuroendocrine carcinoma. These studies are focused on evaluating new anti-cancer treatments for advanced or recurrent disease, especially where current options are limited.
- Testing novel therapies for aggressive neuroendocrine cancers
- Measuring anti-tumour activity and treatment safety in advanced cancer
- Exploring improved care strategies for patients after prior treatment has failed
By participating in these studies, Uniwersytecki Szpital Kliniczny W Poznaniu is helping expand research into difficult-to-treat cancers and potential new options for patients with advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Merck Sharp & Dohme LLC1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Szpital Kliniczny W Poznaniu
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) | Myokardia Inc. | Phase III | Not Recruiting | Sep 2019 | Jan 2026 |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ticagrelor | 3 | Unknown | 2021-07-31 | 2024-12-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.